Nicole Witzmann Named CFO at InfanDx

InfanDx AG has appointed Nicole Witzmann as chief financial officer (CFO). 

Witzmann replaces Dr. Andreas Lischka, who headed InfanDx’s finance department as an external advisor since January 2021. Dr. Lischka left the company to pursue other opportunities, but will remain available for an extended period to ensure a smooth transition for Witzmann.  

“We are very pleased that Nicole joins our management team,” commented Plum. “Having worked with her for some time in a previous position, I am convinced that she will add exactly the skills and experience that we need to further develop InfanDx into a fully integrated diagnostics company providing innovation for neonatal acute and critical care. I would also like to take the opportunity to wholeheartedly thank Dr. Lischka for his services to InfanDx that were invaluable in repositioning and growing the company since I took over as CEO in January 2021.” 
 
Witzmann has more than eight years of experience in corporate finance in the healthcare industry and joins the company from Adrenomed AG, where she served several years as head of Finance. As CFO, Witzmann is now responsible for general administration, accounting and controlling, financial reporting, and—together with CEO Dr. Achim Plum—investor relations and fundraising. At present, the company is preparing a Series B financing round, which is expected to close towards the end of this year or early next year. 
 
“I feel very honored to be part of InfanDx´ management team in the future,” said Witzmann. “As a mother of three, with my youngest son born only a few months ago, I feel particularly close to InfanDx´ vision and mission. I am excited and eager to help bring the InfanDx HypoxE Test for hypoxic-ischemic encephalopathy to the market as it bears the chance to prevent severe lasting injuries of children affected by oxygen deficit during birth.”
 
InfanDx AG is a privately held company developing and commercializing diagnostic solutions for acute and critical care conditions in newborns. The company’s proprietary lead product in clinical development is the InfanDx HypoxE Test designed for the reliable identification of hypoxic-ischemic encephalopathy (HIE) within the first hours of life. HIE as a consequence of perinatal asphyxia (oxygen deficit during birth) can result in life-long disabilities. The long-term detrimental effects of HIE can be mitigated and even prevented by neuroprotective hypothermia treatment. However, this therapy must be initiated within six hours after birth to be effective, requiring suitable diagnostic methods to reliably and timely identify the affected newborns. While standard-of-care diagnostic methods cannot deliver a conclusive diagnosis of HIE within this time frame, the rapid InfanDx HypoxE Test is designed to support clinicians in the timely decision whether newborns require neuroprotective hypothermia treatment. 
 
The company is headquartered in Cologne, Germany, with a branch office in Berlin, Germany, and a wholly owned subsidiary in Boston.